Professional Documents
Culture Documents
Male 5/6/2023
Nitish Rai
©Mapmygenome MMG013071MMP0523540 1
©Mapmygenome MMG013071MMP0523540 2
SNAPSHOT OF YOUR DNA RESULTS
BETA BLOCKER
STATINS
ANTICOAGULANTS
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 3
ANTICOAGULANTS
ANTIARYTHMICS
VASODILATORS
ANTIPLATELET
ANTIHYPERTENSIVES
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 4
SULPHONYL UREA ANTIDIABETICS
BIGUANIDE
ANTIPSYCHOTICS
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 5
ANTIPSYCHOTICS
Chlorpromazine Chlorpromazine,
Chlorotame
TRICYCLIC ANTI-DEPRESSANTS
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 6
TRICYCLIC ANTI-DEPRESSANTS
Protriptyline Vivactil
AMINOKETONE ANTIDEPRESSANTS
ANXIOLYTICS
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 7
OPIOID ANTAGONISTS
EUGEROICS
TETRACYCLIC ANTIDEPRESSANT
ANTIVIRALS
Simeprevir Olysio
Boceprevir Victrelis
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 8
ANTIMALRIALS
ANTIFUNGALS
ANTIBACTERIALS
Mafenide Sulfamylon
ANTIBIOTIC
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 9
ANTIBIOTIC
ANTITUBERCULOSIS DRUG
ANTICONVULSANTS
ACETYLCHOLINESTERASE INHIBITORS
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 10
ACETYLCHOLINESTERASE INHIBITORS
URATE OXIDASES
Pegloticase Krystexxa
IMMUNOSUPRESSANTS
Siponimod Mayzent
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 11
STEROIDS
ANTIDOTES
Succimer Chemet
ANTIMETABOLITES
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 12
KINASE INHIBITOR THERAPEUTICS
Dabrafenib Tafinlar
IMMUNOSUPPRESSANTS
ANTHRACYCLINES
ANTINEOPLASTICS
IMMUNOMODULATORS
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 13
IMMUNOMODULATORS
OPIOIDS
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 14
OPIOIDS
BRONCHODILATORS
MUSCLE RELAXANTS
LAXATIVES
ANALGESICS
ANAESTHETICS
Desflurane Suprane
Enflurane Ethrane
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 15
ANAESTHETICS
Halothane Fluothane
ANTI-ASTHAMATIC
ANTI HISTAMINES
ANTIEMETIC
BISPHOSPHONATE
HEMATOLOGY
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 16
HEMATOLOGY
OTHERS
Eliglustat Cerdelga
Dextro Nuedexta
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 17
YOUR DETAILED
GENETIC REPORT
©Mapmygenome MMG013071MMP0523540 18
PROPRANOLOL
ABOUT
Speciality & class: Cardiology & Beta blockers
Usage: Used in treatment of angina, hypertension, cardiac conditions & migraine.
Brands: Ciplar, Probeta, Inderal La, Albeta, Arminol, Betabloc, Betabus
IMPACT OF GENES
The Arg16Gly polymorphism in the ADRB2 (beta-2 adrenergic receptor) gene causes inter-
individual variation in cirrhosis patients receiving propranolol treatment. The presence of the effect
allele may cause therapy failure in some patients.
Gene : ADRB2
Your Genotype: AG
Interpretation:
According to your genotype, there is a likelihood for slightly reduced response during propranolol
therapy - for lowering variceal pressure during liver cirrhosis. However, your physician shall decide on
the drug and the dose depending on other clinical factors or medications you might be taking.
Evidence:
FDA and EMA
REFERENCES
Kong DR, Wang JG, Sun B, et al.-2 Adrenergic receptor gene polymorphism and response to
propranolol in cirrhosis. World J Gastroenterol. 2015;21(23):7191-7196. doi:10.3748/wjg.v21.i23.7191
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 19
ATORVASTATIN
ABOUT
Speciality & class: Cardiology & Statins
Usage: Lipid lowering drug used to treat coronary heart disease.
Brands: Atocor, Lipitor, Biotor, Atorfit, Atorlip, Dyslip, Cholestat
IMPACT OF GENES
A genetic variant in the Apolipoprotein E (APOE) gene is associated with LDL-cholesterol (Low
Density Lipoprotein) lowering, i.e., statin response. Individuals who carry the APOE gene variant
(rarer form) are more likely to experience clinical response to atorvastatin.
Gene : APOE
Your Genotype: CC
Interpretation:
This indicates that your genetic inclination of having an effective response for the drug therapy may
be reduced. However, your physician shall decide on the drug and the dose depending on other
clinical factors or medications you might be taking.
Evidence:
CPIC, Swissmedic, PMDA and HCSC
REFERENCES
Thompson JF, Man M, Johnson KJ, et al. An association study of 43 SNPs in 16 candidate genes with
atorvastatin response. Pharmacogenomics J. 2005;5(6):352-358. doi:10.1038/sj.tpj.6500328
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 20
ISOSORBIDE AND HYDRALAZINE (BIDIL)
ABOUT
Speciality & class: Cardiology & Vasolidators
Usage: Used as an adjunct in the treatment of heart failure and hypertension.
Brands: Sorbitrate Hf, Isolazine, Nitrohart, Apresol Plus, Bidil
IMPACT OF GENES
N-acetyl transferase 2 (NAT2) is an important enzyme involved in xenobiotic- and drugrelated
metabolic reactions. Individuals carrying at least two slow-acetylator variants in the NAT2 gene are
classified slow acetylators, and may be exposed to elevated plasma drug concentrations, due to
reduced drug clearance. Some studies have reported a link between slow acetylators and drug-
induced adverse effects. On the other hand, fast or rapid acetylators are more likely to require
higher drug doses due to possible therapy failure, due to rapid metabolism and subtherapeutic
plasma concentrations.
Gene : NAT2
Interpretation:
According to your genotypes, the drug may be metabolized very slowly and result in increased plasma
concentrations. This can cause adverse reactions, due to toxicity. However, your physician shall decide
on the drug and the dose depending on other clinical factors or medications you might be taking.
Evidence:
FDA
REFERENCES
McDonagh EM, Boukouvala S, Aklillu E, Hein DW, Altman RB, Klein TE. PharmGKB summary: very
important pharmacogene information for N-acetyltransferase 2. Pharmacogenet Genomics. 2014;
24(8):409-425. doi:10.1097/FPC.0000000000000062
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 21
TICAGRELOR
ABOUT
Speciality & class: Cardiology & Antiplatelet (Platelet aggregation inhibitors)
Usage: Used for the prevention of heart attack and stroke and to reduce the risk of
thrombotic cardiovascular events in unstable angina or myocardial infarction.
Brands: Brilinta, Axcer, Ticagold, Tigemac
IMPACT OF GENES
Genetic elements significantly determine the response of patients to the drug. People with
specific marker in their genotype are unable to metabolize the drug efficiently. Hence, the drug is
accumulated in the muscles leading to muscle toxicity or myopathy. SLCO1B1 gene encodes the
protein OATP1B1, which is associated with hepatic uptake of the drug. Variation in gene sequence
of SLCO1B1 impairs the normal function of the encoded protein, altering the plasma concentration
of statins and increasing related muscle damage.
Gene : SLCO1B1
Your Genotype: AG
Interpretation:
According to your genotype, you may have increased concentrations of ticagrelor . However, your
physician shall decide on the drug and the dose depending on other clinical factors or medications
you might be taking.
Evidence:
FDA and EMA
REFERENCES
Varenhorst C, Eriksson N, Johansson A, et al. Effect of genetic variations on ticagrelor plasma levels
and clinical outcomes. Eur Heart J. 2015;36(29):1901-1912. doi:10.1093/eurheartj/ehv116
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 22
HYDROCHLOROTHIAZIDE
ABOUT
Speciality & class: Cardiology & Antihypertensive
Usage: Used to treat edema associated with heart, liver, kidney or lung disease and
hypertension.
Brands: Aquazide, Hydrazide, Hydride, Thiazide
IMPACT OF GENES
The ACE gene encodes for making the angiotensin-converting enzyme which has the ability to
cleave (cut) proteins. It is a component of the renin-angiotensin system, which controls blood
pressure and salt and fluid balance of body. It converts angiotensin I to angiotensin II which causes
blood vessels to narrow which results in increased blood pressure.
Gene : ADD1
Your Genotype: TG
Interpretation:
According to your genotype, you may have slightly high genetic risk for decreased response of the
drug. However, your physician shall decide on the drug and the dose depending on other clinical
factors or medications you might be taking.
Evidence:
Literature
REFERENCES
Choi HD, Suh JH, Lee JY, et al. Effects of ACE and ADD1 gene polymorphisms on blood pressure
response to hydrochlorothiazide: a meta-analysis. Int J Clin Pharmacol Ther. 2013;51(9):718-724. doi:
10.5414/CP201899
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 23
GLIPIZIDE
ABOUT
Speciality & class: Diabetology & Sulfonylurea Antidiabetics
Usage: Antihyperglycemic agent used in the treatment of Type 2 Diabetes.
Brands: Diaglip, Glyzip, Glynase, Glycind, Glydal, Glucotrol, Gluconil
IMPACT OF GENES
The G6PD enzyme maintains the level of NADPH in red blood cells, for protection against oxidative
stress. In case of its deficiency, the red blood cells are depleted of NADPH which denatures
hemoglobin. This results in hemolysis, i.e., destruction of red blood cells, both in intra- and
extravascular domains. Individuals carrying G6PD mutations are at risk for drug-induced AHA
(acute hemolytic anemia) and may need to monitored regularly, via complete blood count tests.
The U.S Food and Drug Administration (FDA) has issued a warning regarding the potential hazard
of administering certain drugs such as sulfonylureas (eg., glipizide), antidepressants, antimalarials,
etc.
Gene : G6PD
Interpretation:
According to your genotypes, you are heterozygous for G6PD variants which can cause enzyme
deficiency. Hence, the drug can trigger hemolytic anaemia as an adverse effect. However, your
physician shall decide on the drug and the dose depending on other clinical factors or medications
you might be taking.
Evidence:
FDA and CPIC
REFERENCES
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 24
GLIMEPERIDE
ABOUT
Speciality & class: Diabetology & Sulfonylurea Antidiabetics
Usage: Antihyperglycemic agent used in the treatment of Type 2 Diabetes.
Brands: Glimestar, Glimy, Glimiprex, Glypride, Euglim
IMPACT OF GENES
The G6PD enzyme maintains the level of NADPH in red blood cells, for protection against oxidative
stress. In case of its deficiency, the red blood cells are depleted of NADPH which denatures
hemoglobin. This results in hemolysis, i.e., destruction of red blood cells, both in intra- and
extravascular domains. Individuals carrying G6PD mutations are at risk for drug-induced AHA
(acute hemolytic anemia) and may need to monitored regularly, via complete blood count tests.
The U.S Food and Drug Administration (FDA) has issued a warning regarding the potential hazard
of administering certain drugs such as sulfonylureas (eg., glipizide), antidepressants, antimalarials,
etc.
Gene : G6PD
Interpretation:
According to your genotypes, you are heterozygous for G6PD variants which can cause enzyme
deficiency. Hence, the drug can trigger hemolytic anaemia as an adverse effect. However, your
physician shall decide on the drug and the dose depending on other clinical factors or medications
you might be taking.
Evidence:
FDA, EMA, Swissmedic and HCSC
REFERENCES
McDonagh EM, Thorn CF, Bautista JM, Youngster I, Altman RB, Klein TE. PharmGKB summary: very
important pharmacogene information for G6PD. Pharmacogenet Genomics. 2012;22(3):219-228. doi:
10.1097/FPC.0b013e32834eb313
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 25
CHLORPROMAZINE
ABOUT
Speciality & class: Psychiatry & antipsychotics (Phenothiazine antipsychotics)
Usage: Used to treat nausea, vomiting, pre-operative anxiety, schizophrenia, bipolar
disorder and ADHD.
Brands: Chlorpromazine, Chlorotame, Largactil, Clozine
IMPACT OF GENES
The EPM2A gene encodes for a protein called laforin. Although this protein is active in cells
throughout the body, it appears to play a critical role in the survival of neurons and is involved in
regulating brain homeostasis, particularly concerning glycogen metabolism. Polymorphisms in
this gene may gives rise to the accumulation of Lafora bodies, which consist of an unmetabolized
form of glycogen, polyglucosans, which is associated with progressive neurological deterioration.
Gene : EPM2A
Your Genotype: TC
Interpretation:
According to your genotype, you may have slightly decreased response to the drug. However, your
physician shall decide on the drug and the dose depending on other clinical factors or medications
you might be taking.
Evidence:
Literature
REFERENCES
Porcelli S, Balzarro B, Lee SJ, et al. PDE7B, NMBR and EPM2A Variants and Schizophrenia: A Case-
Control and Pharmacogenetics Study. Neuropsychobiology. 2016;73(3):160-168. doi:10.1159
/000445295
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 26
LURASIDONE
ABOUT
Speciality & class: Psychiatry & Antipsychotics
Usage: Used to treat schizophrenia and depressive episodes associated with bipolar
disorder.
Brands: Latuda, Luramax, Lurasid, Altura, Lurafic
IMPACT OF GENES
A functional HTR1A polymorphism, is associated with mood disorders and schizophrenia, Selective
Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics and Signal Transduction pathway are
some of the patways associated with HTR1A. Genetic variants in this gene may affect these
pathways.
Gene : HTR1A
Your Genotype: GC
Interpretation:
This indicates that your genetic inclination of having an effective response for the drug therapy may
be slightly high. However, your physician shall decide on the drug and the dose depending on other
clinical factors or medications you might be taking.
Evidence:
Literature
REFERENCES
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 27
AMISULPURIDE
ABOUT
Speciality & class: Psychiatry & Antipsychotics (Second generation atypical antipsychotics)
Usage: Used in the treatment of acute and chronic schizophrenia, and in the
prevention and treatment of postoperative nausea and vomiting in adults.
Brands: Cizorest, Sulpitac, Soltus, Amisant
IMPACT OF GENES
MC4R gene encodes the MC4 protein, a G protein-coupled receptor that binds alpha-melanocyte
stimulating hormone (a-MSH). This protein is expressed in several areas of the brain, including the
paraventricular nucleus of the hypothalamus, which has an essential role in energy homeostasis.
Activation of MC4R by a-MSH increases the satiety signal and suppresses food intake, regulating
energy balance and body weight.
Gene : MC4R
Your Genotype: AC
Interpretation:
According to your genotype, you may be at a slightly high risk of experiencing side effects like weight
gain and hypertriglyceridemia, when treated with drug. However, your physician shall decide on the
drug and the dose depending on other clinical factors or medications you might be taking.
Evidence:
Literature
REFERENCES
Malhotra AK, Correll CU, Chowdhury NI, et al. Association between common variants near the
melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch Gen
Psychiatry. 2012;69(9):904-912. doi:10.1001/archgenpsychiatry.2012.191
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 28
PALIPERIDONE
ABOUT
Speciality & class: Psychiatry & Antipsychotics (Second generation atypical antipsychotics)
Usage: Used in the treatment of schizophrenia and other schizoaffective or delusional
disorders.
Brands: Invega, Invega Hafyera, Xeplion
IMPACT OF GENES
MC4R gene encodes the MC4 protein, a G protein-coupled receptor that binds alpha-melanocyte
stimulating hormone (a-MSH). This protein is expressed in several areas of the brain, including the
paraventricular nucleus of the hypothalamus, which has an essential role in energy homeostasis.
Activation of MC4R by a-MSH increases the satiety signal and suppresses food intake, regulating
energy balance and body weight.
Gene : MC4R
Your Genotype: TC
Interpretation:
According to your genotype, you may be at a slightly high risk of experiencing weight gain when
treated with drug. Other genetic and clinical factors may also influence risk of experiencing weight
gain when treated with drug. However, your physician shall decide on the drug and the dose
depending on other clinical factors or medications you might be taking.
Evidence:
FDA, EMA, Swissmedic and HCSC
REFERENCES
Czerwensky F, Leucht S, Steimer W. MC4R rs489693: a clinical risk factor for second generation
antipsychotic-related weight gain?. Int J Neuropsychopharmacol. 2013;16(9):2103-2109. doi:10.1017
/S1461145713000849
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 29
QUETIAPINE
ABOUT
Speciality & class: Psychiatry & Antipsychotics (Second generation atypical antipsychotics)
Usage: Used for the management of bipolar disorder, schizophrenia and major
depressive disorder.
Brands: Quel, Q-mind, Seroquin, Adequet, Qutipin
IMPACT OF GENES
MC4R gene encodes the MC4 protein, a G protein-coupled receptor that binds alpha-melanocyte
stimulating hormone (a-MSH). This protein is expressed in several areas of the brain, including the
paraventricular nucleus of the hypothalamus, which has an essential role in energy homeostasis.
Activation of MC4R by a-MSH increases the satiety signal and suppresses food intake, regulating
energy balance and body weight.
Gene : MC4R
Your Genotype: TC
Interpretation:
According to your genotype, you may be at a slightly high risk of experiencing weight gain when
treated with drug. Other genetic and clinical factors may also influence risk of experiencing weight
gain when treated with drug. However, your physician shall decide on the drug and the dose
depending on other clinical factors or medications you might be taking.
Evidence:
Literature
REFERENCES
Czerwensky F, Leucht S, Steimer W. MC4R rs489693: a clinical risk factor for second generation
antipsychotic-related weight gain?. Int J Neuropsychopharmacol. 2013;16(9):2103-2109. doi:10.1017
/S1461145713000849
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 30
TRIFLUOPERAZINE
ABOUT
Speciality & class: Psychiatry & antipsychotics (typical antipsychotics)
Usage: Used to treat depression, anxiety and schizophrenia.
Brands: Espazine, Talecalm, Trazine, Elicalm
IMPACT OF GENES
The EPM2A gene encodes for a protein called laforin. Although this protein is active in cells
throughout the body, it appears to play a critical role in the survival of neurons and is involved in
regulating brain homeostasis, particularly concerning glycogen metabolism. Polymorphisms in
this gene may gives rise to the accumulation of Lafora bodies, which consist of an unmetabolized
form of glycogen, polyglucosans, which is associated with progressive neurological deterioration.
Gene : EPM2A
Your Genotype: TC
Interpretation:
According to your genotype, you may have slightly decreased response towards the drug. However,
your physician shall decide on the drug and the dose depending on other clinical factors or
medications you might be taking.
Evidence:
Literature
REFERENCES
Porcelli S, Balzarro B, Lee SJ, et al. PDE7B, NMBR and EPM2A Variants and Schizophrenia: A Case-
Control and Pharmacogenetics Study. Neuropsychobiology. 2016;73(3):160-168. doi:10.1159
/000445295
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 31
FLUOXETINE
ABOUT
Speciality & class: Psychiatry & Antidepressant (Selective serotonin reuptake inhibitor)
Usage: Used to treat major depressive disorder, obsessive-compulsive disorder,
bulimia nervosa, bipolar and panic disorder
Brands: Flunil, Fluxain, Zedep, Vibodep
IMPACT OF GENES
The membrane-associated protein encoded by this gene is a member of the superfamily of ATP-
binding cassette (ABC) transporters. ABC proteins transport various molecules across extra- and
intra-cellular membranes. Polymorphisms in ABCB1 might be associated with Fluoxetine
treatment responses.
Gene : ABCB1
Your Genotype: TT
Interpretation:
According to your genotype, you may have a decreased likelihood of remission as compared to
patients other genotypes. Other genetic and clinical factors may also influence a patient's response to
antidepressants. However, your physician shall decide on the drug and the dose depending on other
clinical factors or medications you might be taking.
Evidence:
FDA and Swissmedic
REFERENCES
Uhr M, Tontsch A, Namendorf C, et al. Polymorphisms in the drug transporter gene ABCB1 predict
antidepressant treatment response in depression. Neuron. 2008;57(2):203-209. doi:10.1016/j.neuron.
2007.11.017
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 32
SERTRALINE
ABOUT
Speciality & class: Psychiatry & Selective Serotonin Reuptake Inhibitors
Usage: Antidepressant used in the treatment of obsessive-compulsive disorder (OCD),
depression, anxiety- and mood-related disorders such as post-traumatic stress
disorder (PTSD), panic attacks, premenstrual syndrome, etc.
Brands: Zosert, Daxid, Asert, Zoloft, Xsert, Setraline, Setalin
IMPACT OF GENES
According to some studies, 50-60% of patients do not find SSRI treatment effective, because of
genetic and non-genetic factors (eg., stress). Sertraline is metabolized by the CYP2C19 and CYP2D6
enzymes. Genetic variation in CYP2C19 influences drug response as well as risk for adverse effects.
Ultrarapid CYP2C19 metabolizers who are homozygous for the *17 allele, display very low
circulating drug concentrations, and may require alternate drug (which is not metabolized by
CYP2C19 and does not inhibit CYP2D6). These individuals are at risk for failed therapy. According to
the U.S Food and Drug Administration, CYP2C19 poor metabolizers (2-15% of patients) may require
a drastic dose reduction (~50%), to avoid adverse events.
Gene : CYP2C19
Interpretation:
According to your genotypes, the drug may be metabolized too quickly and affect clinical response,
due to subtherapeutic plasma drug concentrations. Alternate therapy may be required. However, your
physician shall decide on the drug and the dose depending on other clinical factors or medications
you might be taking.
Evidence:
CPIC
REFERENCES
Hicks JK, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium
(CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake
Inhibitors. Clin Pharmacol Ther. 2015;98(2):127-134. doi:10.1002/cpt.147
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 33
CITALOPRAM
ABOUT
Speciality & class: Psychiatry & Selective Serotonin Reuptake Inhibitors
Usage: Antidepressant used in the treatment of obsessive-compulsive disorder (OCD),
depression, anxiety- and mood-related disorders such as post-traumatic stress
disorder (PTSD).
Brands: Citopam, Ciprexa, Celexa, C-Pram, Celica, Citadep, Feliz
IMPACT OF GENES
According to some studies, 50-60% of patients do not find SSRI treatment effective, because of
genetic and non-genetic factors (eg., stress). Citalopram, and its active form (S-enantiomer known
as escitalopram), are metabolized by the CYP2C19 enzyme. Genetic variation in CYP2C19 influences
drug response as well as risk for adverse effects. Ultrarapid CYP2C19 metabolizers who are
homozygous for the *17 allele, display very low circulating drug concentrations, and may require
alternate drug (which is not metabolized by CYP2C19 and does not inhibit CYP2D6). These
individuals are at risk for failed therapy. According to the U.S Food and Drug Administration,
CYP2C19 poor metabolizers (2-15% of patients) may require a drastic dose reduction (~50%), to
avoid adverse events such as cardiac arrhythmia.
Gene : CYP2C19
Interpretation:
According to your genotypes, the drug may be metabolized too quickly and affect clinical response,
due to subtherapeutic plasma drug concentrations. Alternate therapy may be required. However, your
physician shall decide on the drug and the dose depending on other clinical factors or medications
you might be taking.
Evidence:
FDA, CPIC, Swissmedic and HCSC
REFERENCES
Hicks JK, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium
(CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake
Inhibitors. Clin Pharmacol Ther. 2015;98(2):127-134. doi:10.1002/cpt.147
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 34
ESCITALOPRAM
ABOUT
Speciality & class: Psychiatry & Selective Serotonin Reuptake Inhibitors
Usage: Antidepressant used in the treatment of obsessive-compulsive disorder (OCD),
depression, anxiety- and mood-related disorders such as post-traumatic stress
disorder (PTSD).
Brands: Cipralex, Alwel, Articalm, Ecitalop, Szetalo, Alivate, Stalopam, Ezeepam, Nexito,
Esdep, Escitapax
IMPACT OF GENES
According to some studies, 50-60% of patients do not find SSRI treatment effective, because of
genetic and non-genetic factors (eg., stress). Citalopram, and its active form (S-enantiomer known
as escitalopram), are metabolized by the CYP2C19 enzyme. Genetic variation in CYP2C19 influences
drug response as well as risk for adverse effects. Ultrarapid CYP2C19 metabolizers who are
homozygous for the *17 allele, display very low circulating drug concentrations, and may require
alternate drug (which is not metabolized by CYP2C19 and does not inhibit CYP2D6). These
individuals are at risk for failed therapy. According to the U.S Food and Drug Administration,
CYP2C19 poor metabolizers (2-15% of patients) may require a drastic dose reduction (~50%), to
avoid adverse events such as cardiac arrhythmia.
Gene : CYP2C19
Interpretation:
According to your genotypes, the drug may be metabolized too quickly and affect clinical response,
due to subtherapeutic plasma drug concentrations. Alternate therapy may be required. However, your
physician shall decide on the drug and the dose depending on other clinical factors or medications
you might be taking.
Evidence:
FDA
REFERENCES
Hicks JK, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium
(CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake
Inhibitors. Clin Pharmacol Ther. 2015;98(2):127-134. doi:10.1002/cpt.147
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 35
CLOMIPRAMINE
ABOUT
Speciality & class: Psychiatry & Tricyclic Antidepressants
Usage: Antidepressants prescribed for pain management during migraine (interval
therapy), depression, obsessive-compulsive disorder (OCD).
Brands: Clomistar, Clomidep, Clofranil, Clomifril, Anafranil, Clomip, Ocifril, Syconil
IMPACT OF GENES
Tricyclic Antidepressants (TCAs) are metabolized by the CYP2D6 and CYP2C19 enzymes of the
cytochrome p450 family of proteins. Poor metabolizers (reduced cytochrome enzyme activity) are
at risk for adverse effects, due to elevated plasma drug concentrations. Ultra metabolizers (greater
cytochrome enzyme activity) may experience failure in treatment (due to subtherapeutic drug
concentrations). Genetic analysis of the CYP2D6 and CYP2C19 markers is used to determine
metabolizer status of an individual and thereby, preferred range of dosing. However, there is
limited data on combinatorial phenotypes (from CYP2D6 and CYP2C19 genotypes). Intermediate
(1-13% of patients) and poor metabolizers (1-10% of patients) may be prescribed a lowered dose of
the TCA. In some cases, an alternate antidepressant (not metabolized by CYP2D6 or CYP2C19) may
be prescribed by the physician. In case of no alternative, stringent monitoring of patient response
to the TCA is essential, after a reduced dose of the same drug.
Gene : CYP2C19
Interpretation:
According to your genotype, the drug may be metabolized too quickly and affect clinical response,
due to subtherapeutic plasma drug concentrations. Alternate therapy may be required. However, your
physician shall decide on the drug and the dose depending on other clinical factors or medications
you might be taking.
Evidence:
FDA,CPIC and Swissmedic
REFERENCES
Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium
guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016
update. Clin Pharmacol Ther. 2017;102(1):37-44. doi:10.1002/cpt.597
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 36
NALTREXONE
ABOUT
Speciality & class: Psychiatry & Opioid Antagonists
Usage: Opioid antagonist for the management of substance abuse disorders.
Brands: Naltreat, Naltrox, Gigadict, Nodict, Naltima, Naltrex, Revia, Contrave, Vivitrol
IMPACT OF GENES
A certain polymorphism in the Mu-opioid receptor (OPRM1) gene enhances an individual's
likelihood of successful therapy with naltrexone. Presence of the variant is associated with reduced
cravings, lesser withdrawal symptoms and an increased period of abstinence. Asians have a
greater frequency for this gene variant, when compared with other populations. The same variant
is linked with alcoholism risk.
Gene : OPRM1
Your Genotype: AA
Interpretation:
According to your genotypes, this drug may be activated to a lesser extent and therapy could be less
effective on you. However, your physician shall decide on the drug and the dose depending on other
clinical factors or medications you might be taking.
Evidence:
CPIC
REFERENCES
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 37
MODAFINIL
ABOUT
Speciality & class: Psychiatry & Eugeroics
Usage: Antinarcoleptic agent used to manage sleep disorders
Brands: Modalert, Modfil, Provigil, Provake, Modatec, Modapro
IMPACT OF GENES
The Val158Met polymorphism in the COMT gene is linked with cognitive behavior, sleep pattern,
pain threshold and memory. Interindividual differences in brain activity during situations of high
anxiety, stress and aversive stimuli can be explained by such genetic variation. Homozygous
carriers of the Met allele (AA genotype) respond poorly to modafinil. This is due to a G to A
substitution in the COMT gene sequence, which results is 35% lesser enzyme activity in the brain.
Gene : COMT
Your Genotype: AA
Interpretation:
According to your genotype, you have two copies of the genetic variant which affects Modafinil
response and hence standard therapy may not be effective. However, your physician shall decide on
the drug and the dose depending on other clinical factors or medications you might be taking.
Evidence:
FDA
REFERENCES
Heinzerling KG, McCracken JT, Swanson AN, Ray LA, Shoptaw SJ. COMT Val158Met, BDNF Val66Met,
and OPRM1 Asn40Asp and methamphetamine dependence treatment response: preliminary
investigation. J Clin Psychopharmacol. 2012;32(1):135-137. doi:10.1097/JCP.0b013e318240a48e
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 38
MIRTAZAPINE
ABOUT
Speciality & class: Psychiatry & Antidepressant (Tetracyclic antidepressant)
Usage: Used in the treatment of major depression
Brands: Mirtaz, Mirnite, Mirtakem, Mirtadep
IMPACT OF GENES
Mirtazapine is metabolized by the CYP2D6 enzyme of the cytochrome p450 family of proteins.
Genetic analysis of the CYP2D6 markers is used to determine metabolizer status and thereby,
preferred range of dosing.
Gene : RABEP1
Your Genotype: AG
Interpretation:
According to your genotype, you may have increased levels of fasting glucose. However, your physician
shall decide on the drug and the dose depending on other clinical factors or medications you might
be taking.
Evidence:
Literature
REFERENCES
Delacretaz A, Zdralovic A, Vandenberghe F, et al. Association of variants in SH2B1 and RABEP1 with
worsening of low-density lipoprotein and glucose parameters in patients treated with psychotropic
drugs. Gene. 2017;628:8-15. doi:10.1016/j.gene.2017.07.005
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 39
METHYLENEBLUE
ABOUT
Speciality & class: Others & Antidotes
Usage: Treatment of drug-induced encephalopathy, malaria and as an antidote.
Brands: Proveblue, Urolene Blue, Provayblue, Uro Blue
IMPACT OF GENES
The G6PD enzyme maintains the level of NADPH in red blood cells, for protection against oxidative
stress. In case of its deficiency, the red blood cells are depleted of NADPH which denatures
hemoglobin. This results in hemolysis, i.e., destruction of red blood cells, both in intra- and
extravascular domains. Individuals carrying G6PD mutations are at risk for drug-induced AHA
(acute hemolytic anemia) and may need to be monitored regularly, via complete blood count
tests. The U.S Food and Drug Administration (FDA) has issued a warning regarding the potential
hazard of administering certain drugs such as sulfonylureas (eg., glipizide), antidepressants,
antimalarials, etc.
Gene : G6PD
Interpretation:
According to your genotypes, you are heterozygous for G6PD variants which can cause enzyme
deficiency. Hence, the drug can trigger hemolytic anaemia as an adverse effect. However, your
physician shall decide on the drug and the dose depending on other clinical factors or medications
you might be taking.
Evidence:
FDA, EMA and PMDA
REFERENCES
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 40
ABACAVIR
ABOUT
Speciality & class: Infectious Disease & Antivirals
Usage: Treatment of HIV infection.
Brands: Abamune, A-Bec, Virol, Ziagen
IMPACT OF GENES
HLA-B gene plays a role in presenting the antigen to the immune system. Variations in this gene
trigger severe HSR in the mutants (HLA-B*5701). Southwest Asians, particularly Indians have the
highest prevalence rate of HLA-B*5701 of up to 20% of population. Up to 8% of patients taking
abacavir experience hypersensitive reaction if genetic pre- screening is not performed. Therefore,
genetic pre-screening of HLA-B*5701 variant is recommended by the United States Food and Drug
Administration (FDA) before starting or re-starting the drug therapy in patients.
Gene : HLA-B*5701
Your Genotype: TG
Interpretation:
This indicates that you may be genetically susceptible for developing drug induced hypersensitive
reaction. Hence you may be given an alternate therapy. However, your physician shall decide on the
drug and the dose depending on other clinical factors or medications you might be taking.
Evidence:
FDA, CPIC, EMA, Swissmedic, PMDA and HCSC
REFERENCES
Berka N, Gill JM, Liacini A, O'Bryan T, Khan FM. Human leukocyte antigen (HLA) and
pharmacogenetics: screening for HLA-B*57:01 among human immunodeficiency virus-positive
patients from southern Alberta. Hum Immunol. 2012;73(2):164-167. doi:10.1016/j.humimm.2011.12.002
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 41
CHLOROQUINE
ABOUT
Speciality & class: Infectious Disease & Antimalarials
Usage: Used in the prevention and treatment of acute parasitic infection.
Brands: Lariago, Nivaquine, Chloroquine, Emquin, Aralen, Malarex, C-Quine
IMPACT OF GENES
The G6PD enzyme maintains the level of NADPH in red blood cells, for protection against oxidative
stress. In case of its deficiency, the red blood cells are depleted of NADPH which denatures
hemoglobin. This results in hemolysis, i.e., destruction of red blood cells, both in intra- and
extravascular domains. Individuals carrying G6PD mutations are at risk for drug-induced AHA
(acute hemolytic anemia) and may need to be monitored regularly, via complete blood count
tests. The U.S Food and Drug Administration (FDA) has issued a warning regarding the potential
hazard of administering certain drugs such as sulfonylureas (eg., glipizide), antidepressants,
antimalarials, etc.
Gene : G6PD
Interpretation:
According to your genotypes, you are heterozygous for G6PD variants which can cause enzyme
deficiency. Hence, the drug can trigger hemolytic anaemia as an adverse effect. However, your
physician shall decide on the drug and the dose depending on other clinical factors or medications
you might be taking.
Evidence:
FDA, CPIC and Swissmedic
REFERENCES
Fanello CI, Karema C, Avellino P, et al. High risk of severe anaemia after chlorproguanil-
dapsone+artesunate antimalarial treatment in patients with G6PD (A-) deficiency. PLoS One. 2008;
3(12):e4031. doi:10.1371/journal.pone.0004031
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 42
PRIMAQUINE
ABOUT
Speciality & class: Infectious Disease & Antimalarials
Usage: Antimalarial drug used for the radical cure of Plasmodium vivax and ovale.
Brands: Primaquine, Primax, Primacip, Tpquin, Primal, Malirid, Cerviprime
IMPACT OF GENES
The G6PD enzyme maintains the level of NADPH in red blood cells, for protection against oxidative
stress. In case of its deficiency, the red blood cells are depleted of NADPH which denatures
hemoglobin. This results in hemolysis, i.e., destruction of red blood cells, both in intra- and
extravascular domains. Individuals carrying G6PD mutations are at risk for drug-induced AHA
(acute hemolytic anemia) and may need to be monitored regularly, via complete blood count
tests. The U.S Food and Drug Administration (FDA) has issued a warning regarding the potential
hazard of administering certain drugs such as sulfonylureas (eg., glipizide), antidepressants,
antimalarials, etc.
Gene : G6PD
Interpretation:
According to your genotypes, you are heterozygous for G6PD variants which can cause enzyme
deficiency. Hence, the drug can trigger hemolytic anaemia as an adverse effect. However, your
physician shall decide on the drug and the dose depending on other clinical factors or medications
you might be taking.
Evidence:
FDA, CPIC and HCSC
REFERENCES
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 43
QUININESULPHATE
ABOUT
Speciality & class: Infectious Disease & Antimalarials
Usage: An antibiotic drug for treating bacterial infections.
Brands: Quinine, Chinine, Cinkona, Mosgard, Q-9, Quinlup, Nine, Zequin
IMPACT OF GENES
The G6PD enzyme maintains the level of NADPH in red blood cells, for protection against oxidative
stress. In case of its deficiency, the red blood cells are depleted of NADPH which denatures
hemoglobin. This results in hemolysis, i.e., destruction of red blood cells, both in intra- and
extravascular domains. Individuals carrying G6PD mutations are at risk for drug-induced AHA
(acute hemolytic anemia) and may need to be monitored regularly, via complete blood count
tests. The U.S Food and Drug Administration (FDA) has issued a warning regarding the potential
hazard of administering certain drugs such as sulfonylureas (eg., glipizide), antidepressants,
antimalarials, etc.
Gene : G6PD
Interpretation:
According to your genotypes, you are heterozygous for G6PD variants which can cause enzyme
deficiency. Hence, the drug can trigger hemolytic anaemia as an adverse effect. However, your
physician shall decide on the drug and the dose depending on other clinical factors or medications
you might be taking.
Evidence:
FDA, Swissmedic and HCSC
REFERENCES
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 44
VORICONAZOLE
ABOUT
Speciality & class: Infectious Disease & Antifungals
Usage: Antifungal agent used in the treatment of aspergillosis.
Brands: Vorier, Voritrol, Vorizole, Voraze, Verz, Vosicaz, Vfend
IMPACT OF GENES
Genetic variation in CYP2C19 influences drug response as well as risk for adverse effects.
Individuals who carry two no-function alleles display greater plasma drug concentrations.
According to the U.S Food and Drug Administration, CYP2C19 poor metabolizers (2-15% of patients)
may require an alternate drug.
Gene : CYP2C19
Interpretation:
According to your genotypes, the drug may be metabolized too quickly and affect clinical response,
due to subtherapeutic plasma drug concentrations. Alternate therapy may be required. However, your
physician shall decide on the drug and the dose depending on other clinical factors or medications
you might be taking.
Evidence:
FDA, CPIC, EMA, Swissmedic, PMDA and HCSC
REFERENCES
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 45
DAPSONE
ABOUT
Speciality & class: Infectious Disease & Antibacterials
Usage: Treatment of leprosy, skin infection, burns, wounds, etc
Brands: Dapsone, Acnedap, Acnesone, Aczone, Udolac, Tarimyl, Sulfona
IMPACT OF GENES
The G6PD enzyme maintains the level of NADPH in red blood cells, for protection against oxidative
stress. In case of its deficiency, the red blood cells are depleted of NADPH which denatures
hemoglobin. This results in hemolysis, i.e., destruction of red blood cells, both in intra- and
extravascular domains. Individuals carrying G6PD mutations are at risk for drug-induced AHA
(acute hemolytic anemia) and may need to be monitored regularly, via complete blood count
tests. The U.S Food and Drug Administration (FDA) has issued a warning regarding the potential
hazard of administering certain drugs such as sulfonylureas (eg., glipizide), antidepressants,
antimalarials, etc.
Gene : G6PD
Interpretation:
According to your genotypes, you are heterozygous for G6PD variants which can cause enzyme
deficiency. Hence, the drug can trigger hemolytic anaemia as an adverse effect. However, your
physician shall decide on the drug and the dose depending on other clinical factors or medications
you might be taking.
Evidence:
FDA, CPIC, PMDA and HCSC
REFERENCES
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 46
MAFENIDE
ABOUT
Speciality & class: Infectious Disease & Antibacterials
Usage: Treatment of skin infection, burns, wounds, etc.
Brands: Sulfamylon
IMPACT OF GENES
The G6PD enzyme maintains the level of NADPH in red blood cells, for protection against oxidative
stress. In case of its deficiency, the red blood cells are depleted of NADPH which denatures
hemoglobin. This results in hemolysis, i.e., destruction of red blood cells, both in intra- and
extravascular domains. Individuals carrying G6PD mutations are at risk for drug-induced AHA
(acute hemolytic anemia) and may need to be monitored regularly, via complete blood count
tests. The U.S Food and Drug Administration (FDA) has issued a warning regarding the potential
hazard of administering certain drugs such as sulfonylureas (eg., glipizide), antidepressants,
antimalarials, etc.
Gene : G6PD
Interpretation:
According to your genotypes, you are heterozygous for G6PD variants which can cause enzyme
deficiency. Hence, the drug can trigger hemolytic anaemia as an adverse effect. However, your
physician shall decide on the drug and the dose depending on other clinical factors or medications
you might be taking.
Evidence:
FDA, CPIC and HCSC
REFERENCES
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 47
NALIDIXIC ACID
ABOUT
Speciality & class: Infectious Disease & Antibacterials
Usage: Antibacterial agent used in the treatment of urinary tract infections.
Brands: Ulix, Urex, Negamet, Nal-P, Wintron, Uronidix, Gramoneg, Dix, Negadix
IMPACT OF GENES
The G6PD enzyme maintains the level of NADPH in red blood cells, for protection against oxidative
stress. In case of its deficiency, the red blood cells are depleted of NADPH which denatures
hemoglobin. This results in hemolysis, i.e., destruction of red blood cells, both in intra- and
extravascular domains. Individuals carrying G6PD mutations are at risk for drug-induced AHA
(acute hemolytic anemia) and may need to be monitored regularly, via complete blood count
tests. The U.S Food and Drug Administration (FDA) has issued a warning regarding the potential
hazard of administering certain drugs such as sulfonylureas (eg., glipizide), antidepressants,
antimalarials, etc.
Gene : G6PD
Interpretation:
According to your genotypes, you are heterozygous for G6PD variants which can cause enzyme
deficiency. Hence, the drug can trigger hemolytic anaemia as an adverse effect. However, your
physician shall decide on the drug and the dose depending on other clinical factors or medications
you might be taking.
Evidence:
FDA and PMDA
REFERENCES
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 48
NITROFURANTOIN
ABOUT
Speciality & class: Infectious Disease & Antibacterials
Usage: Antibacterial agent used in the treatment of urinary tract infections.
Brands: Niftran, Uribid, Nitfur, Urifast, Niftas, Martifur, Urinif
IMPACT OF GENES
The G6PD enzyme maintains the level of NADPH in red blood cells, for protection against oxidative
stress. In case of its deficiency, the red blood cells are depleted of NADPH which denatures
hemoglobin. This results in hemolysis, i.e., destruction of red blood cells, both in intra- and
extravascular domains. Individuals carrying G6PD mutations are at risk for drug-induced AHA
(acute hemolytic anemia) and may need to be monitored regularly, via complete blood count
tests. The U.S Food and Drug Administration (FDA) has issued a warning regarding the potential
hazard of administering certain drugs such as sulfonylureas (eg., glipizide), antidepressants,
antimalarials, etc.
Gene : G6PD
Interpretation:
According to your genotypes, you are heterozygous for G6PD variants which can cause enzyme
deficiency. Hence, the drug can trigger hemolytic anaemia as an adverse effect. However, your
physician shall decide on the drug and the dose depending on other clinical factors or medications
you might be taking.
Evidence:
FDA, CPIC, Swissmedic and HCSC
REFERENCES
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 49
FLUCLOXACILLIN
ABOUT
Speciality & class: Infectious Disease & Antibiotic
Usage: An antibiotic drug for treating bacterial infections.
Brands: Floxapen, Staphonex, Stafocin, Stafocid
IMPACT OF GENES
Genes involved in the metabolism of the drug in connection to its adverse reaction are not well
known. However, MHC loci may share a crucial role in determining the drug response of an
individual. Several genes like TNF, HSPA1L, HLA and ST6GAL1 may correlate with drug induced liver
injury. The MHC loci HLA-B*5701 has a greater significance of association with drug toxicity. HLA-
B*5701 is commonly detected by screening for its tag marker rs2395029. One out of 500-1000
people with HLA-B*5701 marker may have liver toxicity when treated with the drug. However,
cases of liver toxicity with HLA-B*5701 are hardly seen in Asian countries.
Gene : HLA-B*5701
Your Genotype: TG
Interpretation:
This indicates that you may be genetically susceptible to develop drug induced toxicity. Hence you
may be recommended a low dose of the drug or an alternate therapy. However, your physician shall
decide on the drug and the dose depending on other clinical factors or medications you might be
taking.
Evidence:
Swissmedic
REFERENCES
Daly AK, Donaldson PT, Bhatnagar P, et al. HLA-B*5701 genotype is a major determinant of drug-
induced liver injury due to flucloxacillin. Nat Genet. 2009;41(7):816-819. doi:10.1038/ng.379
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 50
ISONIAZID
ABOUT
Speciality & class: Infectious Disease & Antituberculosis drug
Usage: Used for active and latent tuberculosis
Brands: Solonex, Lup Inh, Isonij, Isoniazid
IMPACT OF GENES
N-acetyltransferase 2 (NAT2) is an important enzyme involved in xenobiotic- and drug related
metabolic reactions. Individuals carrying at least two slow-acetylator variants in the NAT2 gene are
classified slow acetylators, and may be exposed to levated plasma drug concentrations, due to
reduced drug clearance. Some studies have reported a link between slow acetylators and drug-
induced adverse effects such as toxicity. On the other hand, fast or rapid acetylators are more likely
to require higher drug doses due to possible therapy failure, due to rapid metabolism and
subtherapeutic plasma concentrations, but this needs further validation.
Gene : NAT2
Interpretation:
According to your genotypes, the drug may be metabolized very slowly and result in increased plasma
concentrations. This can cause adverse reactions, due to toxicity. However, your physician shall decide
on the drug and the dose depending on other clinical factors or medications you might be taking.
Evidence:
FDA and PMDA
REFERENCES
An HR, Wu XQ, Wang ZY, Zhang JX, Liang Y. NAT2 and CYP2E1 polymorphisms associated with
antituberculosis drug-induced hepatotoxicity in Chinese patients. Clin Exp Pharmacol Physiol. 2012;
39(6):535-543. doi:10.1111/j.1440-1681.2012.05713.x
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 51
PYRAZINAMIDE
ABOUT
Speciality & class: Infectious Disease & Antituberculosis drug
Usage: Used for active and latent tuberculosis
Brands: Pyzina, P Zide, Macrozide, Pyra, Pza Ciba
IMPACT OF GENES
N-acetyltransferase 2 (NAT2) is an important enzyme involved in xenobiotic- and drug related
metabolic reactions. Individuals carrying at least two slow-acetylator variants in the NAT2 gene are
classified slow acetylators, and may be exposed to levated plasma drug concentrations, due to
reduced drug clearance. Some studies have reported a link between slow acetylators and drug-
induced adverse effects such as toxicity. On the other hand, fast or rapid acetylators are more likely
to require higher drug doses due to possible therapy failure, due to rapid metabolism and
subtherapeutic plasma concentrations, but this needs further validation.
Gene : NAT2
Interpretation:
According to your genotypes, the drug may be metabolized very slowly and result in increased plasma
concentrations. This can cause adverse reactions, due to toxicity. However, your physician shall decide
on the drug and the dose depending on other clinical factors or medications you might be taking.
Evidence:
FDA
REFERENCES
An HR, Wu XQ, Wang ZY, Zhang JX, Liang Y. NAT2 and CYP2E1 polymorphisms associated with
antituberculosis drug-induced hepatotoxicity in Chinese patients. Clin Exp Pharmacol Physiol. 2012;
39(6):535-543. doi:10.1111/j.1440-1681.2012.05713.x
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 52
ETHAMBUTOL
ABOUT
Speciality & class: Infectious Disease & Antituberculosis drug
Usage: Used for active and latent tuberculosis
Brands: Combutal, Zytham, Mycobutol, Ecox, Themibutol
IMPACT OF GENES
N-acetyltransferase 2 (NAT2) is an important enzyme involved in xenobiotic- and drug related
metabolic reactions. Individuals carrying at least two slow-acetylator variants in the NAT2 gene are
classified slow acetylators, and may be exposed to levated plasma drug concentrations, due to
reduced drug clearance. Some studies have reported a link between slow acetylators and drug-
induced adverse effects such as toxicity. On the other hand, fast or rapid acetylators are more likely
to require higher drug doses due to possible therapy failure, due to rapid metabolism and
subtherapeutic plasma concentrations, but this needs further validation.
Gene : NAT2
Interpretation:
According to your genotypes, the drug may be metabolized very slowly and result in increased plasma
concentrations. This can cause adverse reactions, due to toxicity. However, your physician shall decide
on the drug and the dose depending on other clinical factors or medications you might be taking.
Evidence:
Literature
REFERENCES
An HR, Wu XQ, Wang ZY, Zhang JX, Liang Y. NAT2 and CYP2E1 polymorphisms associated with
antituberculosis drug-induced hepatotoxicity in Chinese patients. Clin Exp Pharmacol Physiol. 2012;
39(6):535-543. doi:10.1111/j.1440-1681.2012.05713.x
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 53
RIFAMPIN
ABOUT
Speciality & class: Infectious Disease & Antibacterials
Usage: Treatment of Mycobacterium Tuberculosis (TB)
Brands: R-Cin, Rifacept, Montomycin, Serom, Rifalite, Rifacure
IMPACT OF GENES
N-acetyltransferase 2 (NAT2) is an important enzyme involved in xenobiotic- and drug related
metabolic reactions. Individuals carrying at least two slow-acetylator variants in the NAT2 gene are
classified as slow acetylators, and may be exposed to elevated plasma drug concentrations, due to
reduced drug clearance resulting in adverse effects such as toxicity. On the other hand, fast or
rapid acetylators are more likely to require higher drug doses due to possible therapy failure, due
to rapid metabolism and subtherapeutic plasma concentrations, but needs further validation.
Gene : NAT2
Interpretation:
According to your genotypes, the drug may be metabolized very slowly and result in increased plasma
concentrations. This can cause adverse reactions, due to toxicity. However, your physician shall decide
on the drug and the dose depending on other clinical factors or medications you might be taking.
Evidence:
FDA
REFERENCES
An HR, Wu XQ, Wang ZY, Zhang JX, Liang Y. NAT2 and CYP2E1 polymorphisms associated with
antituberculosis drug-induced hepatotoxicity in Chinese patients. Clin Exp Pharmacol Physiol. 2012;
39(6):535-543. doi:10.1111/j.1440-1681.2012.05713.x
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 54
RIVASTIGMINE
ABOUT
Speciality & class: Alzheimer Disease Agents, cholinesterase inhibitor
Usage: Used to treat neurodegenerative disease causing mild to moderate dementia
like Alzheimers and Parkinsons disease
Brands: Exelon, Rivamer, Rivasmine, Ritas
IMPACT OF GENES
The CHRNA7 gene on chromosome 15 encodes a cholinergic receptor. These nicotinic
acetylcholine receptors (nAChRs) are members of a superfamily of ligand-gated ion channels that
mediate fast signal transmission at synapses. After binding acetylcholine, the AChR responds by
an extensive change in conformation that affects all subunits and leads to opening of an ion-
conducting channel across the plasma membrane.
Gene : CHRNA7
Your Genotype: TC
Interpretation:
According to your genotype, there is a likelihood for slightly reduced response to treatment with
rivastagmine. However, your physician shall decide on the drug and the dose depending on other
clinical factors or medications you might be taking.
Evidence:
Literature
REFERENCES
Braga IL, Silva PN, Furuya TK, et al. Effect of APOE and CHRNA7 genotypes on the cognitive
response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease. Am
J Alzheimers Dis Other Demen. 2015;30(2):139-144. doi:10.1177/1533317514539540
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 55
MEMANTINE
ABOUT
Speciality & class: Neurology & Alzheimer Disease Agents (N-methyl-D-aspartate (NMDA)
receptor antagonist)
Usage: Used in the treatment of Alzheimers and dementia
Brands: Admenta, Ebixa, Marixino, Almantin, Namenda, Namzaric
IMPACT OF GENES
The NR1I2 gene codes for the pregnane X receptor (PXR) which is a member of the nuclear
receptor (NR) superfamily of transcription factors that regulates the induction of many genes.
Activation of PXR may result in disturbance in drug metaboslim causing toxicity.
Gene : NR1I2
Your Genotype: TC
Interpretation:
According to your genotype, you may have slightly faster clearance of Memantine. Other genetic and
clinical factors may also influence a patient's response to antidepressants. However, your physician
shall decide on the drug and the dose depending on other clinical factors or medications you might
be taking.
Evidence:
Literature
REFERENCES
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 56
DONEPEZIL
ABOUT
Speciality & class: Neurology & Alzheimer Disease Agents (acetylcholinesterase inhibitor)
Usage: Used to treat the behavioral and cognitive effects of Alzheimers disease and
other types of dementia.
Brands: Donep, Donecept, Adlarity, Aricept, Namzaric
IMPACT OF GENES
The CHAT gene provides instructions for making a protein called choline acetyltransferase. Choline
acetyltransferase facilitates the production of a molecule called acetylcholine. Acetylcholine is
essential for normal muscle movement.
Gene : CHRNA7
Your Genotype: TC
Interpretation:
According to your genotype, there is a likelihood for slightly reduced response to treatment with
donepezil. However, your physician shall decide on the drug and the dose depending on other clinical
factors or medications you might be taking.
Evidence:
FDA
REFERENCES
Braga IL, Silva PN, Furuya TK, et al. Effect of APOE and CHRNA7 genotypes on the cognitive
response to cholinesterase inhibitor treatment at different stages of Alzheimers disease. Am J
Alzheimers Dis Other Demen. 2015;30(2):139-144. doi:10.1177/1533317514539540
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 57
RASBURICASE
ABOUT
Speciality & class: Urology & Urate Oxidases
Usage: Treatment of hyperuricemia, chemotherapy induced elevated urate levels.
Brands: Rasby, Rascas, Rasuric, Elitek, Fasturtec, Rasuritek
IMPACT OF GENES
G6PD deficiency, is an inherited condition caused by mutations in the G6PD gene on
chromosome X. The G6PD enzyme maintains the level of NADPH in red blood cells, for protection
against oxidative stress. In case of G6PD deficiency, the red blood cells are depleted of NADPH
which triggers a series of chemical reactions that oxidize hemoglobin to a denatured protein. This
results in hemolysis, i.e., destruction of red blood cells, both in intra- and extravascular domains.
Individuals carrying G6PD mutations are at risk for drug-induced acute hemolytic anemia and
may need to be monitored regularly.
Gene : G6PD
Interpretation:
According to your genotypes, you are heterozygous for G6PD variants which can cause enzyme
deficiency. Hence, the drug can trigger hemolytic anaemia as an adverse effect. However, your
physician shall decide on the drug and the dose depending on other clinical factors or medications
you might be taking.
Evidence:
FDA, CPIC, EMA, Swissmedic, PMDA and HCSC
REFERENCES
Relling MV, McDonagh EM, Chang T, et al. Clinical Pharmacogenetics Implementation Consortium
(CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype. Clin
Pharmacol Ther. 2014;96(2):169-174. doi:10.1038/clpt.2014.97
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 58
PEGLOTICASE
ABOUT
Speciality & class: Urology & Urate Oxidases
Usage: Treatment of hyperuricemia and refractory gout.
Brands: Krystexxa
IMPACT OF GENES
G6PD (Glucose-6 Phosphate Dehydrogenase) deficiency, or favism, is an inherited condition
caused by mutations in the G6PD gene on chromosome X. The G6PD enzyme maintains the level
of NADPH in red blood cells, for protection against oxidative stress. In case of G6PD deficiency, the
red blood cells are depleted of NADPH which triggers a series of chemical reactions that oxidize
hemoglobin to a denatured protein. This results in hemolysis, i.e., destruction of red blood cells,
both in intra- and extravascular domains. Individuals carrying G6PD mutations are at risk for drug-
induced AHA (acute hemolytic anemia) and may need to be monitored regularly, via complete
blood count tests.
Gene : G6PD
Interpretation:
According to your genotypes, you are heterozygous for G6PD variants which can cause enzyme
deficiency. Hence, the drug can trigger hemolytic anaemia as an adverse effect. However, your
physician shall decide on the drug and the dose depending on other clinical factors or medications
you might be taking.
Evidence:
FDA, CPIC and EMA
REFERENCES
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 59
METHOTREXATE
ABOUT
Speciality & class: Immunology & Immunosuppressants
Usage: Treatment of cancers, hydatidiform mole and autoimmune diseases.
Brands: Mexate, Imutrex, Merex, Mext, Biotrexate, Caditrex, Auratrex, Carditrex,
Dermatrex
IMPACT OF GENES
Genetic studies have identified a strong link between MTHFR (methylenetetrahydrofolate
reductase) gene and methotrexate toxicity (adverse effects). Sequence variation in MTHFR can
reduce enzyme activity and thus lower the overall production of purines, which increases the risk
for drug-induced toxicity. Individuals who carry one or two copies of the C677T MTHFR risk variant
may be at higher risk for adverse effects, when compared to those with the normal genotype.
Gene : MTHFR
Your Genotype: AG
Interpretation:
According to your genotype, you have one copy of the genetic variant which increases drug sensitivity
and risk for adverse effects. Standard therapy may be less effective. However, your physician shall
decide on the drug and the dose depending on other clinical factors or medications you might be
taking.
Evidence:
Literature
REFERENCES
van Ede AE, Laan RF, Blom HJ, et al. The C677T mutation in the methylenetetrahydrofolate
reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in
rheumatoid arthritis patients. Arthritis Rheum. 2001;44(11):2525-2530. doi:10.1002/1529-0131(200111)44:
11<2525::aid-art432>3.0.co;2-b
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 60
TACROLIMUS
ABOUT
Speciality & class: Immunology & Immunosuppressants
Usage: Prevents graft rejection after transplantation, topical agent in dermatitis.
Brands: Tacromus, Tacros, Tacroderm, Tacrograf, Tacroderm, Tacrokid
IMPACT OF GENES
Individuals with genetic variants of CYP3A5 (cytochrome p450 3A5) may be poor metabolizers of
the drug, and may require standard doses. Extensive and intermediate metabolizers may require
higher doses of the drug.
Gene : CYP3A5
Interpretation:
According to your genotypes, this drug may be metabolized less rapidly and therapy could be
effective. However, your physician shall decide on the drug and the dose depending on other clinical
factors or medications you might be taking.
Evidence:
FDA and CPIC
REFERENCES
Birdwell KA, Decker B, Barbarino JM, et al. Clinical Pharmacogenetics Implementation Consortium
(CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clin Pharmacol Ther. 2015;98(1):19-
24. doi:10.1002/cpt.113
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 61
MYCOPHENOLATE MOFETIL
ABOUT
Speciality & class: Immunology & Immunosuppressants
Usage: Used to prevent graft rejections post organ transplantation and to treat
autoimmune conditions
Brands: Mycept, Cellcept, Mycofit, Mycomune
IMPACT OF GENES
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome
P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism
and synthesis of cholesterol, steroids and other lipids. The enzyme is known to metabolize many
xenobiotics, including the anticonvulsive drug mephenytoin, benzo(a)pyrene, 7-ethyoxycoumarin,
and the anti-cancer drug taxol.
Gene : IL10
Your Genotype: TG
Interpretation:
According to your genotype, there may be slightly increased risk for biopsy-proven acute rejection
(BPAR). Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute
rejection. However, your physician shall decide on the drug and the dose depending on other clinical
factors or medications you might be taking.
Evidence:
Literture
REFERENCES
Grinyo J, Vanrenterghem Y, Nashan B, et al. Association of four DNA polymorphisms with acute
rejection after kidney transplantation. Transpl Int. 2008;21(9):879-891. doi:10.1111/j.1432-
2277.2008.00679.x
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 62
DEXAMETHASONE
ABOUT
Speciality & class: Immunology & Steroid (Glucocorticoid)
Usage: Used to treat inflammatory and autoimmune conditions.
Brands: Dexona, Dexasone, Decamycin, Decadron
IMPACT OF GENES
The CTNNB1 gene encodoes for a protein called beta-catenin and is also involves in WnT signalling
pathway. THis pathway triggers a multistep process that allows the protein to move into the cell
nucleus. The Wnt signaling pathway promotes the growth and proliferation of cells.
Gene : CTNNB1
Your Genotype: AG
Interpretation:
According to your genotype, you may have slightly high risk for decreased response towards the drug
therapy. Other clinical and genetic factors may also influence changes in intraocular pressure in
patients with retinal disease. However, your physician shall decide on the drug and the dose
depending on other clinical factors or medications you might be taking.
Evidence:
Literture
REFERENCES
Butrym A, Rybka J, Lacina P, et al. Polymorphisms within beta-catenin encoding gene affect
multiple myeloma development and treatment. Leuk Res. 2015;39(12):1462-1466. doi:10.1016/j.leukres.
2015.10.007
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 63
FLUTICASONE PROPIONATE
ABOUT
Speciality & class: Immunology & Steroid (Glucocorticoid)
Usage: Used to manage and treat asthma, allergic rhinitis, emphysema and atopic
dermatitis
Brands: Flutivate, Flomist, Flutiflo, Fluticone, Floresp
IMPACT OF GENES
This gene encodes a protein which catalyze the reversible hydration of carbon dioxide in various
biological processes. The protein encoded by this geneplay a role in the central nervous system,
especially in brain development.
Gene : CA10
Your Genotype: TC
Interpretation:
According to your genotype, you may have slightly poor response to drug therapy. However, your
physician shall decide on the drug and the dose depending on other clinical factors or medications
you might be taking.
Evidence:
Literature
REFERENCES
Perin P, Potonik U. Polymorphisms in recent GWA identified asthma genes CA10, SGK493, and
CTNNA3 are associated with disease severity and treatment response in childhood asthma.
Immunogenetics. 2014;66(3):143-151. doi:10.1007/s00251-013-0755-0
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 64
TRIAMCINOLONE
ABOUT
Speciality & class: Immunology & Steroids (Corticosteroid)
Usage: Used to treat a wide variety of inflammatory conditions of organ systems and
tissues such as allergies, ulcerative colitis, arthritis, lupus, psoriasis, or breathing
disorders.
Brands: Ledercort, Aristocort, Stancort, Oraways
IMPACT OF GENES
Human leukocyte antigens (HLA) are genes in major histocompatibility complexes that help code
for proteins that differentiate between self and non-self. They play a significant role in disease and
immune defense. They are beneficial to the immune system but can also have detrimental effects.
HLA COMPLEX GROUP 22 (HCG22) is one of the genes from HLA complex.
Gene : HCG22
Your Genotype: TC
Interpretation:
According to your genotype, you may have a slightly increased intraocular pressure when treated with
Triamcinolone. Other clinical and genetic factors may also influence changes in intraocular pressure in
patients with retinal disease. However, your physician shall decide on the drug and the dose
depending on other clinical factors or medications you might be taking.
Evidence:
Literature
REFERENCES
Jeong S, Patel N, Edlund CK, et al. Identification of a Novel Mucin Gene HCG22 Associated With
Steroid-Induced Ocular Hypertension. Invest Ophthalmol Vis Sci. 2015;56(4):2737-2748. doi:10.1167
/iovs.14-14803
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 65
SODIUM NITRITE
ABOUT
Speciality & class: Toxicology & Antidotes
Usage: Antidote of cyanide poisoning in conjunction with sodium thiosulphate.
Brands: Cyanide Antidote Kit, Nithiodote, Cyanokit
IMPACT OF GENES
G6PD (Glucose-6 Phosphate Dehydrogenase) deficiency, or favism, is an inherited condition
caused by mutations in the G6PD gene on chromosome X. The G6PD enzyme maintains the level
of NADPH in red blood cells, for protection against oxidative stress. In case of G6PD deficiency, the
red blood cells are depleted of NADPH which triggers a series of chemical reactions that oxidize
hemoglobin to a denatured protein. This results in hemolysis, i.e., destruction of red blood cells,
both in intra- and extravascular domains. Individuals carrying G6PD mutations are at risk for drug-
induced AHA (acute hemolytic anemia) and may need to be monitored regularly.
Gene : G6PD
Interpretation:
According to your genotypes, you are heterozygous for G6PD variants which can cause enzyme
deficiency. Hence, the drug can trigger hemolytic anaemia as an adverse effect. However, your
physician shall decide on the drug and the dose depending on other clinical factors or medications
you might be taking.
Evidence:
FDA and HCSC
REFERENCES
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 66
SUCCIMER
ABOUT
Speciality & class: Toxicology & Antidotes
Usage: Chelating agent used in lead, mercury, cadmium and arsenic poisoning.
Brands: Chemet
IMPACT OF GENES
G6PD (Glucose-6 Phosphate Dehydrogenase) deficiency, or favism, is an inherited condition
caused by mutations in the G6PD gene on chromosome X. The G6PD enzyme maintains the level
of NADPH in red blood cells, for protection against oxidative stress. In case of G6PD deficiency, the
red blood cells are depleted of NADPH which triggers a series of chemical reactions that oxidize
hemoglobin to a denatured protein. This results in hemolysis, i.e., destruction of red blood cells,
both in intra- and extravascular domains. Individuals carrying G6PD mutations are at risk for drug-
induced AHA (acute hemolytic anemia) and may need to be monitored regularly.
Gene : G6PD
Interpretation:
According to your genotypes, you are heterozygous for G6PD variants which can cause enzyme
deficiency. Hence, the drug can trigger hemolytic anaemia as an adverse effect. However, your
physician shall decide on the drug and the dose depending on other clinical factors or medications
you might be taking.
Evidence:
FDA
REFERENCES
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 67
DABRAFENIB
ABOUT
Speciality & class: Oncology & Kinase Inhibitor Chemotherapeutics
Usage: Used in the treatment of metastatic melanoma.
Brands: Tafinlar
IMPACT OF GENES
Dabrafenib can trigger hemolysis in melanoma patients who are positive for glucose-6-phosphate
dehydrogenase (G6PD) mutations. These individuals are at risk for drug-induced AHA (acute
hemolytic anaemia) and may need to monitored regularly, via complete blood count tests. The U.S
Food and Drug Administration (FDA) has issued a warning regarding the potential hazard of
administering certain drugs such as antidepressants, antimalarials, dabrafenib, etc.
Gene : G6PD
Interpretation:
According to your genotypes, you are heterozygous for G6PD variants which can cause enzyme
deficiency. Hence, the drug can trigger hemolytic anaemia as an adverse effect. However, your
physician shall decide on the drug and the dose depending on other clinical factors or medications
you might be taking.
Evidence:
FDA, EMA and HCSC
REFERENCES
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 68
SUNITINIB
ABOUT
Speciality & class: Oncology & Chemotherapy (Tyrosine kinase inhibitor)
Usage: Used for the treatment of renal cell carcinoma (RCC) and imatinib-resistant
gastrointestinal stromal tumor (GIST).
Brands: Rcnet, Nitnib, Tunib, Sunicine
IMPACT OF GENES
The cytochrome P450 proteins are monooxygenases that catalyse numerous chemical processes
essential for drug metabolism and the production of steroid hormones, cholesterol, and other
lipids. Individuals with genetic variants of CYP3A5 (cytochrome p450 3A5) may be poor
metabolizers of the drug, and may require standard doses. Extensive and intermediate
metabolizers may require higher doses of the drug.
Gene : CYP3A5
Your Genotype: TC
Interpretation:
According to your genotype, the drug might be metabolized to a lesser extent in your body. You might
be susceptible for developing drug induced toxicity (myopathy or muscle toxicity). Hence you may be
recommended a very low dose of the drug or an alternate therapy. However, your physician shall
decide on the drug and the dose depending on other clinical factors or medications you might be
taking.
Evidence:
EMA
REFERENCES
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 69
CYCLOPHOSPHAMIDE
ABOUT
Speciality & class: Oncology & Chemotherapy (Alkylating agents)
Usage: Used to treat cancers like lymphoma, multiple myeloma, leukemia, ovarian
cancer, breast cancer, small cell lung cancer, neuroblastoma, and sarcoma and
also as an immunosuppressant.
Brands: Endoxan, Cycloxan, Cyclocel, Oncomide
IMPACT OF GENES
The CTNNB1 gene encodoes for a protein called beta-catenin and is also involves in WnT signalling
pathway. THis pathway triggers a multistep process that allows the protein to move into the cell
nucleus. The Wnt signaling pathway promotes the growth and proliferation of cells.
Gene : CTNNB1
Your Genotype: AG
Interpretation:
According to your genotype, you may have slightly high risk for decreased response towards the drug
therapy. Other genetic and clinical factors may also influence a patient's response to
cyclophosphamide. However, your physician shall decide on the drug and the dose depending on
other clinical factors or medications you might be taking.
Evidence:
Literature
REFERENCES
Butrym A, Rybka J, Lacina P, et al. Polymorphisms within beta-catenin encoding gene affect
multiple myeloma development and treatment. Leuk Res. 2015;39(12):1462-1466. doi:10.1016/j.leukres.
2015.10.007
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 70
LENALIDOMIDE
ABOUT
Speciality & class: Oncology & Immunomodulator (Anti neoplastic drug)
Usage: Used to treat multiple myeloma and anemia in low to intermediate risk
myelodysplastic syndrome.
Brands: Lenalid, Lenangio, Lenmid, Lenzest, Lenid
IMPACT OF GENES
The CTNNB1 gene encodoes for a protein called beta-catenin and is also involves in WnT signalling
pathway. THis pathway triggers a multistep process that allows the protein to move into the cell
nucleus. The Wnt signaling pathway promotes the growth and proliferation of cells.
Gene : CTNNB1
Your Genotype: AG
Interpretation:
According to your genotype, you have the genetic variant which affects the drug response and can
cause slightly elevated risk for neutropenia. However, your physician shall decide on the drug and the
dose depending on other clinical factors or medications you might be taking.
Evidence:
EMA, PMDA and HCSC
REFERENCES
Butrym A, Rybka J, Jacina P, et al. Polymorphisms within beta-catenin encoding gene affect
multiple myeloma development and treatment. Leuk Res. 2015;39(12):1462-1466. doi:10.1016/j.leukres.
2015.10.007
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 71
ANASTROZOLE
ABOUT
Speciality & class: Oncology & Aromatase inhibitor
Usage: Used to treat breast cancer in postmenopausal women.
Brands: Arimidex, Stazonex, Femistra, Armotraz
IMPACT OF GENES
Estrogen Receptor 1 (ESR1) is a gene that codes for proteins. Breast cancer and oestrogen
resistance are two diseases linked to ESR1. This gene is expressed in many tissues that play a role in
growth, metabolism, sexual development, gestation, and other reproductive functions.
Gene : ESR1
Your Genotype: AG
Interpretation:
According to your genotype, you may have high risk of pain. However, your physician shall decide on
the drug and the dose depending on other clinical factors or medications you might be taking.
Evidence:
FDA and HCSC
REFERENCES
Wang J, Lu K, Song Y, et al. Indications of clinical and genetic predictors for aromatase inhibitors
related musculoskeletal adverse events in Chinese Han women with breast cancer. PLoS One. 2013;
8(7):e68798. Published 2013 Jul 19. doi:10.1371/journal.pone.0068798
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 72
LETROZOLE
ABOUT
Speciality & class: Oncology & Aromatase inhibitor
Usage: Used to treat breast cancer in postmenopausal women.
Brands: Letroz, Letoval, Letrohope, Induz
IMPACT OF GENES
Estrogen Receptor 1 (ESR1) is a gene that codes for proteins. Breast cancer and oestrogen
resistance are two diseases linked to ESR1. This gene is expressed in many tissues that play a role in
growth, metabolism, sexual development, gestation, and other reproductive functions.
Gene : ESR1
Your Genotype: AG
Interpretation:
According to your genotype, you may have high risk of pain. However, your physician shall decide on
the drug and the dose depending on other clinical factors or medications you might be taking.
Evidence:
FDA, PMDA and HCSC
REFERENCES
Wang J, Lu K, Song Y, et al. Indications of clinical and genetic predictors for aromatase inhibitors
related musculoskeletal adverse events in Chinese Han women with breast cancer. PLoS One. 2013;
8(7):e68798. Published 2013 Jul 19. doi:10.1371/journal.pone.0068798
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 73
SALBUTAMOL
ABOUT
Speciality & class: Pulmonology & Bronchodilators
Usage: Used in the treatment of bronchitis, asthma, COPD.
Brands: Asthalin, Salbetol, Asthavent, Astinol, Salbair Resp
IMPACT OF GENES
A polymorphism in the beta-2 adrenergic receptor (ADRB2) gene affects bronchodilator response
in adults and children. This variant causes a Glycine-to-Arginine amino acid change in the gene
product (or protein), which affects cAMP levels and severity of asthma symptoms. Individuals who
are heterozygous or homozygous for the variant (Arg) allele may be poor responders and also
experience worsening of clinical symptoms.
Gene : ADRB2
Your Genotype: AG
Interpretation:
This indicates that your genetic inclination of having an effective response for the drug therapy may
be slightly reduced. However, your physician shall decide on the drug and the dose depending on
other clinical factors or medications you might be taking.
Evidence:
Literature
REFERENCES
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 74
PEG3350
ABOUT
Speciality & class: General Medicine & Laxative
Usage: Laxative used for colon cleansing prior to medical procedures.
Brands: Cipeg, Looz Peg, Pegsure, Muout, Laxolite
IMPACT OF GENES
G6PD (Glucose-6 Phosphate Dehydrogenase) deficiency, is an inherited condition caused by
mutations in the G6PD gene on chromosome X. The G6PD enzyme maintains the level of NADPH
in red blood cells, for protection against oxidative stress. In case of G6PD deficiency, the red blood
cells are depleted of NADPH which triggers a series of chemical reactions that oxidize hemoglobin
to a denatured protein. This results in hemolysis, i.e., destruction of red blood cells, both in intra-
and extravascular domains. Individuals carrying G6PD mutations are at risk for drug-induced AHA
(acute hemolytic anemia) and may need to be monitored regularly, via complete blood count
tests.
Gene : G6PD
Interpretation:
According to your genotypes, you are heterozygous for G6PD variants which can cause enzyme
deficiency. Hence, the drug can trigger hemolytic anaemia as an adverse effect. However, your
physician shall decide on the drug and the dose depending on other clinical factors or medications
you might be taking.
Evidence:
FDA, PMDA and HCSC
REFERENCES
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021881s008medg.pdf
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 75
SALMETEROL
ABOUT
Speciality & class: General Medicine & Anti-asthamatic
Usage: Used to treat moderate-to-severe persistent asthma.
Brands: Salmeter, Serobid, Azrol, Seoflo
Relax respiratory muscles and prevent the onset and worsening of symptoms of asthma.
IMPACT OF GENES
The Arg16Gly polymorphism in the ADRB2 (beta-2 adrenergic receptor) gene causes
interindividual variation in cirrhosis patients receiving propranolol treatment. The presence of the
effect allele may cause therapy failure in some patients.
Gene : ADRB2
Your Genotype: AG
Interpretation:
According to your genotypes, this drug may be activated to a lesser extent and therapy could be less
effective on you. However, your physician shall decide on the drug and the dose depending on other
clinical factors or medications you might be taking.
Evidence:
Literature
REFERENCES
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 76
MONTELUKAST
ABOUT
Speciality & class: General Medicine & Leukotriene receptor antagonist
Usage: Used in the treatment of asthma, exercise-induced bronchoconstriction and
rhinitis.
Brands: Montair, Telekast, Montek, Romilast
IMPACT OF GENES
This gene encodes a protein which catalyze the reversible hydration of carbon dioxide in various
biological processes. The protein encoded by this geneplay a role in the central nervous system,
especially in brain development.
Gene : CA10
Your Genotype: TC
Interpretation:
According to your genotype, you may have slightly poor response to drug therapy. However, your
physician shall decide on the drug and the dose depending on other clinical factors or medications
you might be taking.
Evidence:
Literature
REFERENCES
Perin P, Potonik U. Polymorphisms in recent GWA identified asthma genes CA10, SGK493, and
CTNNA3 are associated with disease severity and treatment response in childhood asthma.
Immunogenetics. 2014;66(3):143-151. doi:10.1007/s00251-013-0755-0
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 77
ALENDRONATE
ABOUT
Speciality & class: General Medicine & Bisphosphonates
Usage: Used to treat osteoporosis in both females and males, also in the prevention
and treatment of steroid-associated osteoporosis, and Pagets disease of the
bone.
Brands: Adrovance, Binosto, Fosamax, Fosavance
IMPACT OF GENES
The vitamin D receptor (VDR) gene codes for the production of a protein that enables the body to
react to vitamin D. Several elements in the body, such as calcium and phosphate, which are
necessary for the healthy development of bones and teeth, are kept in the appropriate balance by
vitamin D.
Gene : VDR
Your Genotype: TC
Interpretation:
According to your genotype, you may have reduced response to the drug and may have less
improvement in bone mineral density. However, your physician shall decide on the drug and the dose
depending on other clinical factors or medications you might be taking.
Evidence:
Literature
REFERENCES
Palomba S, Orio F Jr, Russo T, et al. BsmI vitamin D receptor genotypes influence the efficacy of
antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter,
randomized and controlled trial. Osteoporos Int. 2005;16(8):943-952. doi:10.1007/s00198-004-1800-5
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 78
OMEPRAZOLE
ABOUT
Speciality & class: Gastroenterology & Proton Pump Inhibitors
Usage: Treatment of heartburn & symptoms of Gastro-Esophageal Reflux Disease.
Brands: Omez, Oskar, Omesec, Omicap, Omepren, Omizac, Procid, Protoloc, Skyzole,
Ulzol
IMPACT OF GENES
Omeprazole is metabolized by the CYP2C19 enzyme of the cytochrome p450 family of proteins.
Ultrarapid metabolizers (greater cytochrome enzyme activity) may experience failure in treatment
(due to subtherapeutic drug concentrations). Intermediate and poor metabolizers (reduced
cytochrome enzyme activity) display greater plasma drug concentrations and may experience
successful therapy.
Gene : CYP2C19
Interpretation:
According to your genotype, the drug may be metabolized to a greater extent, and clinical response
may be low, due to subtherapeutic drug concentrations. However, your physician shall decide on the
drug and the dose depending on other clinical factors or medications you might be taking.
Evidence:
FDA, CPIC, Swissmedic, PMDA and HCSC
REFERENCES
Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium
(CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):
1417-1423. doi:10.1002/cpt.2015
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 79
ESOMEPRAZOLE
ABOUT
Speciality & class: Gastroenterology & Proton Pump Inhibitors
Usage: Used in Gastroesophageal Reflux Disease & erosive esophagitis.
Brands: Sompraz, Nexpro, Esoz, Neksium, Esomac, Esofag, Zosec, Stomatix, Raciper, Izra
IMPACT OF GENES
Esomeprazole is metabolized by the CYP2C19 enzyme of the cytochrome p450 family of proteins.
The effect of CYP2C19 genotype on proton pump inhibitor (PPi) efficacy has been extensively
studied. Ultrarapid metabolizers (greater cytochrome enzyme activity) may experience failure in
treatment (due to subtherapeutic drug concentrations). Intermediate and poor metabolizers
(reduced cytochrome enzyme activity) display greater plasma drug concentrations and may
experience successful therapy. However, genotype-based differences in intragastric pH are less
significant in case of esomeprazole, when compared with omeprazole and lansoprazole.
Gene : CYP2C19
Interpretation:
According to your genotype, the drug may be metabolized to a greater extent, and clinical response
may be low, due to subtherapeutic drug concentrations. However, your physician shall decide on the
drug and the dose depending on other clinical factors or medications you might be taking.
Evidence:
FDA, CPIC, EMA, Swissmedic, PMDA and HCSC
REFERENCES
Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium
(CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):
1417-1423. doi:10.1002/cpt.2015
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 80
LANSOPRAZOLE
ABOUT
Speciality & class: Gastroenterology & Proton Pump Inhibitors
Usage: Used in Gastroesophageal Reflux Disease & erosive esophagitis.
Brands: Lanzol, Lanzoprax, Locid, Lanzopen, Lan, Prevacid, Protogut, Zapacid, Lanzap,
Lancid
IMPACT OF GENES
Lansoprazole is metabolized by the CYP2C19 enzyme of the cytochrome p450 family of proteins.
Ultrarapid metabolizers (greater cytochrome enzyme activity) may experience failure in treatment
(due to subtherapeutic drug concentrations). Intermediate and poor metabolizers (reduced
cytochrome nzyme activity) display greater plasma drug concentrations and may experience
successful therapy.
Gene : CYP2C19
Interpretation:
According to your genotype, the drug may be metabolized to a greater extent, and clinical response
may be low, due to subtherapeutic drug concentrations. However, your physician shall decide on the
drug and the dose depending on other clinical factors or medications you might be taking.
Evidence:
FDA, CPIC and Swissmedic
REFERENCES
Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium
(CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):
1417-1423. doi:10.1002/cpt.2015
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 81
PANTOPRAZOLE
ABOUT
Speciality & class: Gastroenterology & Proton Pump Inhibitors
Usage: Used in Gastroesophageal Reflux Disease & erosive esophagitis.
Brands: Pan, Pantop, Pantocid, Pantodac, Pansec, Pantin, Nupenta, Zylpan
IMPACT OF GENES
Pantoprazole is metabolized by the CYP2C19 enzyme of the cytochrome p450 family of proteins.
Ultrarapid metabolizers (greater cytochrome enzyme activity) may experience failure in treatment
(due to subtherapeutic drug concentrations). These individuals may need an higher dose of
pantoprazole, for effective treatment. Intermediate and poor metabolizers (reduced cytochrome
enzyme activity) display greater plasma drug concentrations and may experience successful
therapy.
Gene : CYP2C19
Interpretation:
According to your genotype, the drug may be metabolized to a greater extent, and clinical response
may be low, due to subtherapeutic drug concentrations. However, your physician shall decide on the
drug and the dose depending on other clinical factors or medications you might be taking.
Evidence:
FDA, CPIC and Swissmedic
REFERENCES
Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium
(CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):
1417-1423. doi:10.1002/cpt.2015
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 82
RABEPRAZOLE
ABOUT
Speciality & class: Gastroenterology & Proton Pump Inhibitors
Usage: Treatment of symptoms of GERD, H. pylori infection & peptic ulcer.
Brands: Rabicip, Rabeloc, Rabifast, Rekool, Veloz, Rabemac, Happi
IMPACT OF GENES
Rabeprazole is metabolized by the CYP2C19 enzyme. The effect of the CYP2C19 genotype on
proton pump inhibitor (PPi) efficacy has been extensively studied. Ultrarapid metabolizers (greater
enzyme activity) may experience failure in treatment (due to subtherapeutic drug concentrations).
Intermediate and poor metabolizers (reduced cytochrome activity) display greater plasma drug
concentrations and may experience successful therapy. However, genotype-based differences in
intragastric pH are less significant in the case of rabeprazole, when compared with omeprazole
and lansoprazole.
Gene : CYP2C19
Interpretation:
According to your genotype, the drug may be metabolized to a greater extent, and clinical response
may be low, due to subtherapeutic drug concentrations. However, your physician shall decide on the
drug and the dose depending on other clinical factors or medications you might be taking.
Evidence:
FDA, CPIC, Swissmedic, PMDA and HCSC
REFERENCES
Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium
(CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):
1417-1423. doi:10.1002/cpt.2015
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 83
DEXLANSOPRAZOLE
ABOUT
Speciality & class: Gastroenterology & Proton Pump Inhibitors
Usage: Used for Gastroesophageal Reflux Disease & erosive esophagitis.
Brands: Dexlanzol, Dexolan, Lanfil Dx, Lantas-Dx, Duabit
IMPACT OF GENES
Dexlansoprazole is metabolized by the CYP2C19 enzyme of the cytochrome p450 family of
proteins. Ultrarapid metabolizers (greater cytochrome enzyme activity) may experience failure in
treatment (due to subtherapeutic drug concentrations). Intermediate and poor metabolizers
(reduced cytochrome enzyme activity) display greater plasma drug concentrations and may
experience successful therapy.
Gene : CYP2C19
Interpretation:
According to your genotype, the drug may be metabolized to a greater extent, and clinical response
may be low, due to subtherapeutic drug concentrations. However, your physician shall decide on the
drug and the dose depending on other clinical factors or medications you might be taking.
Evidence:
FDA, CPIC, Swissmedic and HCSC
REFERENCES
Lima JJ, Thomas CD, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium
(CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):
1417-1423. doi:10.1002/cpt.2015
Caution: Do not change or alter the medicines without consulting your doctor
©Mapmygenome MMG013071MMP0523540 84
©Mapmygenome MMG013071MMP0523540 85
©Mapmygenome MMG013071MMP0523540 86